Rhythm Pharmaceuticals (RYTM) PT Raised to $25 at Stifel After BBS Approval
Tweet Send to a Friend
Stifel analyst Dae Gon Ha raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $25.00 (from $23.00) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
